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Abstract
There is a somewhat confused belief that a biomarker must show an interaction effect with a treatment before it can be used
to determine the need for such a treatment. This is rarely true for well-established clinical markers such as tumor size or re-
gional lymph node involvement. In many cases, this is also not true for biomarkers, especially when considering nontargeted
therapies. Here I argue that for nontargeted treatments prognosis is often more important than interaction with treatment,
because it is the absolute and not the relative benefit that matters, and when there is no treatment interaction, the same rela-
tive benefit translates into a larger absolute benefit for poor prognosis patients.
When determining the need for additional treatment, confusion
exists between the importance of a marker capable of predicting
the likelihood of disease recurrence (or progression) vs one that
predicts an interaction with treatment response. The former is
usually referred to as “prognostic value,” whereas the latter has
often been referred to as “prediction” or, more fully, as
“prediction of treatment response.” This is a misnomer that
should be avoided. This is largely due to the fact that treatment
effects need to be assessed in terms of absolute benefits, but
most of the statistical models used are based on relative effect
sizes. Thus a marker that is strongly prognostic for treatment
failure or recurrence but has no interaction with treatment (ie,
the relative effect sizes are similar for high- and low-risk
patients) is still highly predictive of the absolute benefit of treat-
ment. An example is node positivity in breast cancer. This is
one of the strongest prognostic factors for recurrence and an
important factor in deciding the need for chemotherapy, but
there is no interaction with chemotherapy in the conventional
multiplicative proportional hazards model. For example, in the
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
overview, the relative benefit of poly-chemotherapy was similar
in node-positive vs node-negative women. For women younger
than age 50 years, the hazard ratios for recurrence were 0.64 for
N0 vs 0.63 for Nþ women (1). For women age 50 to 69 years,
there was a slightly and statistically nonsignificantly larger rela-
tive benefit in node-negative women (hazard ratio ¼ 0.77 vs
0.83, P ¼ .6), belying the fact that the absolute benefit was
larger in the node-positive women (1.6% vs 0.8% per year,
P ¼ 1.410-6). Thus, while there is no interaction of nodal status
with response to chemotherapy, it is clear that the absolute
benefit of chemotherapy is much greater in node-positive
women, because the same relative benefit translates into a
larger absolute benefit. This is also true for mortality when
comparing chemotherapies with or without anthracyclines and
with or without taxanes (2). Similar results are also seen for
tumor size and grade.
Similar principles are also applicable to a molecular bio-
marker or panel of biomarkers, but here the distinction between
qualitative and quantitative biomarkers is important. A qualita-
tive marker such as estrogen receptor or human epidermal
growth factor receptor 2 (HER2) positivity indicates a qualita-
tively different type of the disease in which different pathways
are activated for tumor growth. In the case where treatment
attacks a specific pathway and the biomarker determines that
that pathway is activated, the marker is truly predictive of re-
sponse to a specific treatment (notably endocrine therapy for
estrogen receptor–positive tumors and trastuzumab and related
drugs for HER2-positive disease, and other monoclonal antibod-
ies, eg, PD-1/PD-L1 blockade in melanoma) (3). However, more
general quantitative markers, such as those measuring the rate
of cell cycle proliferation or metastatic potential (which do not
[yet] identify qualitatively different disease mechanisms) may
not have any impact on the relative effect of a treatment in dif-
ferent subgroups, but by identifying a high-risk subgroup, they
are still important in determining which patients will benefit
most in absolute terms from additional treatment. This
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distinction has been more fully developed elsewhere (4–6),
where the terms “therapy guiding” and “clinical utility” are used
for markers that provide guidance on which patients might ben-
efit most from treatment. Note that this does not require a sig-
nificant interaction, but seeks to separate patients based on
likely absolute benefits and/or harms.
For example, much has been made of the fact that the
Oncotype test showed “predictive value for response to chemo-
therapy” in one trial when used alone (7). However, many newer
tests have not demonstrated an interaction with treatment, but
have shown similar prognostic value to Oncotype in the first
five years of follow-up, and a greater ability to predict late recur-
rence (8,9). One of the problems is that the analysis of interac-
tions with treatment depends heavily on the effect in the low-
risk group, where there are few recurrences and substantial
uncertainties in any conclusion. Another issue is that the inter-
pretation of molecular tests always needs to be made in light of
important standard clinical prognostic factors such as nodal
status and tumor size, and in this trial the interaction between
Oncotype and treatment was no longer significant after ac-
counting for these factors (10).
Thus, quantitative markers that are strongly prognostic but
do not demonstrate a statistical interaction with treatment can
still be highly informative when making a decision about the
use of chemotherapy. To base a decision only on a statistical in-
teraction with treatment (often called predictive value) can be
misleading.
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